A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN.
A form of anemia in which the bone marrow fails to produce adequate numbers of peripheral blood elements.
Injuries resulting when a person is struck by particles impelled with violent force from an explosion. Blast causes pulmonary concussion and hemorrhage, laceration of other thoracic and abdominal viscera, ruptured ear drums, and minor effects in the central nervous system. (From Dorland, 27th ed)
A condition of inadequate circulating red blood cells (ANEMIA) or insufficient HEMOGLOBIN due to premature destruction of red blood cells (ERYTHROCYTES).
Chronic refractory anemia with granulocytopenia, and/or thrombocytopenia. Myeloblasts and progranulocytes constitute 5 to 40 percent of the nucleated marrow cells.
A severe sometimes chronic anemia, usually macrocytic in type, that does not respond to ordinary antianemic therapy.
Congenital disorder affecting all bone marrow elements, resulting in ANEMIA; LEUKOPENIA; and THROMBOPENIA, and associated with cardiac, renal, and limb malformations as well as dermal pigmentary changes. Spontaneous CHROMOSOME BREAKAGE is a feature of this disease along with predisposition to LEUKEMIA. There are at least 7 complementation groups in Fanconi anemia: FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, and FANCL. (from Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=227650, August 20, 2004)
Acquired hemolytic anemia due to the presence of AUTOANTIBODIES which agglutinate or lyse the patient's own RED BLOOD CELLS.
Anemia characterized by a decrease in the ratio of the weight of hemoglobin to the volume of the erythrocyte, i.e., the mean corpuscular hemoglobin concentration is less than normal. The individual cells contain less hemoglobin than they could have under optimal conditions. Hypochromic anemia may be caused by iron deficiency from a low iron intake, diminished iron absorption, or excessive iron loss. It can also be caused by infections or other diseases, therapeutic drugs, lead poisoning, and other conditions. (Stedman, 25th ed; from Miale, Laboratory Medicine: Hematology, 6th ed, p393)
Anemia characterized by larger than normal erythrocytes, increased mean corpuscular volume (MCV) and increased mean corpuscular hemoglobin (MCH).
A megaloblastic anemia occurring in children but more commonly in later life, characterized by histamine-fast achlorhydria, in which the laboratory and clinical manifestations are based on malabsorption of vitamin B 12 due to a failure of the gastric mucosa to secrete adequate and potent intrinsic factor. (Dorland, 27th ed)
Anemia characterized by the presence of erythroblasts containing excessive deposits of iron in the marrow.
A disease characterized by chronic hemolytic anemia, episodic painful crises, and pathologic involvement of many organs. It is the clinical expression of homozygosity for hemoglobin S.
The period of time following the triggering of an ACTION POTENTIAL when the CELL MEMBRANE has changed to an unexcitable state and is gradually restored to the resting (excitable) state. During the absolute refractory period no other stimulus can trigger a response. This is followed by the relative refractory period during which the cell gradually becomes more excitable and the stronger impulse that is required to illicit a response gradually lessens to that required during the resting state.
A disorder characterized by the presence of ANEMIA, abnormally large red blood cells (megalocytes or macrocytes), and MEGALOBLASTS.
The oxygen-carrying proteins of ERYTHROCYTES. They are found in all vertebrates and some invertebrates. The number of globin subunits in the hemoglobin quaternary structure differs between species. Structures range from monomeric to a variety of multimeric arrangements.
A species of LENTIVIRUS, subgenus equine lentiviruses (LENTIVIRUSES, EQUINE), causing acute and chronic infection in horses. It is transmitted mechanically by biting flies, mosquitoes, and midges, and iatrogenically through unsterilized equipment. Chronic infection often consists of acute episodes with remissions.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
Hemolytic anemia due to various intrinsic defects of the erythrocyte.
Glycoprotein hormone, secreted chiefly by the KIDNEY in the adult and the LIVER in the FETUS, that acts on erythroid stem cells of the BONE MARROW to stimulate proliferation and differentiation.
Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.
Viral disease of horses caused by the equine infectious anemia virus (EIAV; INFECTIOUS ANEMIA VIRUS, EQUINE). It is characterized by intermittent fever, weakness, and anemia. Chronic infection consists of acute episodes with remissions.
The type species of GYROVIRUS, a small, non-enveloped DNA virus originally isolated from contaminated vaccines in Japan. It causes chicken infectious anemia and may possibly play a key role in hemorrhagic anemia syndrome, anemia dermatitis, and blue wing disease.
A familial disorder characterized by ANEMIA with multinuclear ERYTHROBLASTS, karyorrhexis, asynchrony of nuclear and cytoplasmic maturation, and various nuclear abnormalities of bone marrow erythrocyte precursors (ERYTHROID PRECURSOR CELLS). Type II is the most common of the 3 types; it is often referred to as HEMPAS, based on the Hereditary Erythroblast Multinuclearity with Positive Acidified Serum test.
A metallic element with atomic symbol Fe, atomic number 26, and atomic weight 55.85. It is an essential constituent of HEMOGLOBINS; CYTOCHROMES; and IRON-BINDING PROTEINS. It plays a role in cellular redox reactions and in the transport of OXYGEN.
A rare congenital hypoplastic anemia that usually presents early in infancy. The disease is characterized by a moderate to severe macrocytic anemia, occasional neutropenia or thrombocytosis, a normocellular bone marrow with erythroid hypoplasia, and an increased risk of developing leukemia. (Curr Opin Hematol 2000 Mar;7(2):85-94)
Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites.
The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells.
A therapeutic approach, involving chemotherapy, radiation therapy, or surgery, after initial regimens have failed to lead to improvement in a patient's condition. Salvage therapy is most often used for neoplastic diseases.
A diverse group of proteins whose genetic MUTATIONS have been associated with the chromosomal instability syndrome FANCONI ANEMIA. Many of these proteins play important roles in protecting CELLS against OXIDATIVE STRESS.
The return of a sign, symptom, or disease after a remission.
The co-occurrence of pregnancy and a blood disease (HEMATOLOGIC DISEASES) which involves BLOOD CELLS or COAGULATION FACTORS. The hematologic disease may precede or follow FERTILIZATION and it may or may not have a deleterious effect on the pregnant woman or FETUS.
The mildest form of erythroblastosis fetalis in which anemia is the chief manifestation.
Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience.
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
Agents which improve the quality of the blood, increasing the hemoglobin level and the number of erythrocytes. They are used in the treatment of anemias.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
Elements of limited time intervals, contributing to particular results or situations.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
The volume of packed RED BLOOD CELLS in a blood specimen. The volume is measured by centrifugation in a tube with graduated markings, or with automated blood cell counters. It is an indicator of erythrocyte status in disease. For example, ANEMIA shows a low value; POLYCYTHEMIA, a high value.
The production of red blood cells (ERYTHROCYTES). In humans, erythrocytes are produced by the YOLK SAC in the first trimester; by the liver in the second trimester; by the BONE MARROW in the third trimester and after birth. In normal individuals, the erythrocyte count in the peripheral blood remains relatively constant implying a balance between the rate of erythrocyte production and rate of destruction.
Therapeutic act or process that initiates a response to a complete or partial remission level.
A Fanconi anemia complementation group protein that regulates the activities of CYTOCHROME P450 REDUCTASE and GLUTATHIONE S-TRANSFERASE. It is found predominately in the CYTOPLASM, but moves to the CELL NUCLEUS in response to FANCE PROTEIN.
Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA.
A Fanconi anemia complementation group protein that undergoes mono-ubiquitination by FANCL PROTEIN in response to DNA DAMAGE. Also, in response to IONIZING RADIATION it can undergo PHOSPHORYLATION by ataxia telangiectasia mutated protein. Modified FANCD2 interacts with BRCA2 PROTEIN in a stable complex with CHROMATIN, and it is involved in DNA REPAIR by homologous RECOMBINATION.
A Fanconi anemia complementation group protein that is the most commonly mutated protein in FANCONI ANEMIA. It undergoes PHOSPHORYLATION by PROTEIN KINASE B and forms a complex with FANCC PROTEIN in the CELL NUCLEUS.
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures.
Disease having a short and relatively severe course.
Iron-containing proteins that are widely distributed in animals, plants, and microorganisms. Their major function is to store IRON in a nontoxic bioavailable form. Each ferritin molecule consists of ferric iron in a hollow protein shell (APOFERRITINS) made of 24 subunits of various sequences depending on the species and tissue types.
Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.
Annual cereal grass of the family POACEAE and its edible starchy grain, rice, which is the staple food of roughly one-half of the world's population.
The number of RED BLOOD CELLS per unit volume in a sample of venous BLOOD.
Antibodies produced by a single clone of cells.
The introduction of whole blood or blood component directly into the blood stream. (Dorland, 27th ed)
Any one of a group of congenital hemolytic anemias in which there is no abnormal hemoglobin or spherocytosis and in which there is a defect of glycolysis in the erythrocyte. Common causes include deficiencies in GLUCOSE-6-PHOSPHATE ISOMERASE; PYRUVATE KINASE; and GLUCOSE-6-PHOSPHATE DEHYDROGENASE.
A clinical manifestation consisting of an unnatural paleness of the skin.
Red blood cells. Mature erythrocytes are non-nucleated, biconcave disks containing HEMOGLOBIN whose function is to transport OXYGEN.
The relationship between the dose of an administered drug and the response of the organism to the drug.
A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.
Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.
ERYTHROCYTE size and HEMOGLOBIN content or concentration, usually derived from ERYTHROCYTE COUNT; BLOOD hemoglobin concentration; and HEMATOCRIT. The indices include the mean corpuscular volume (MCV), the mean corpuscular hemoglobin (MCH), and the mean corpuscular hemoglobin concentration (MCHC).
Measurement of hemoglobin concentration in blood.
Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.
Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration.
A subnormal level of BLOOD PLATELETS.
The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it.
Leukemia associated with HYPERPLASIA of the lymphoid tissues and increased numbers of circulating malignant LYMPHOCYTES and lymphoblasts.
A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.
The number of LEUKOCYTES and ERYTHROCYTES per unit volume in a sample of venous BLOOD. A complete blood count (CBC) also includes measurement of the HEMOGLOBIN; HEMATOCRIT; and ERYTHROCYTE INDICES.
Antibodies obtained from a single clone of cells grown in mice or rats.
An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
Proteins prepared by recombinant DNA technology.
Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.
A measure of the quality of health care by assessment of unsuccessful results of management and procedures used in combating disease, in individual cases or series.
A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.
Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging.
Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations.
A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care. (Dictionary of Health Services Management, 2d ed)
A Fanconi anemia complementation group protein that undergoes PHOSPHORYLATION by CDC2 PROTEIN KINASE during MITOSIS. It forms a complex with other FANCONI ANEMIA PROTEINS and helps protect CELLS from DNA DAMAGE by genotoxic agents.
A test to detect non-agglutinating ANTIBODIES against ERYTHROCYTES by use of anti-antibodies (the Coombs' reagent.) The direct test is applied to freshly drawn blood to detect antibody bound to circulating red cells. The indirect test is applied to serum to detect the presence of antibodies that can bind to red blood cells.
The number of RETICULOCYTES per unit volume of BLOOD. The values are expressed as a percentage of the ERYTHROCYTE COUNT or in the form of an index ("corrected reticulocyte index"), which attempts to account for the number of circulating erythrocytes.
The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.
Iron or iron compounds used in foods or as food. Dietary iron is important in oxygen transport and the synthesis of the iron-porphyrin proteins hemoglobin, myoglobin, cytochromes, and cytochrome oxidase. Insufficient amounts of dietary iron can lead to iron-deficiency anemia.
Cells contained in the bone marrow including fat cells (see ADIPOCYTES); STROMAL CELLS; MEGAKARYOCYTES; and the immediate precursors of most blood cells.
A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence.
Therapy with two or more separate preparations given for a combined effect.
Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.
Deficiency of all three cell elements of the blood, erythrocytes, leukocytes and platelets.
Progenitor cells from which all blood cells derive.
The total number of cases of a given disease in a specified population at a designated time. It is differentiated from INCIDENCE, which refers to the number of new cases in the population at a given time.
Organic and inorganic compounds that contain iron as an integral part of the molecule.
Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals.
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
Drugs used to prevent SEIZURES or reduce their severity.
Forms of hepcidin, a cationic amphipathic peptide synthesized in the liver as a prepropeptide which is first processed into prohepcidin and then into the biologically active hepcidin forms, including in human the 20-, 22-, and 25-amino acid residue peptide forms. Hepcidin acts as a homeostatic regulators of iron metabolism and also possesses antimicrobial activity.
Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.
The highest dose of a biologically active agent given during a chronic study that will not reduce longevity from effects other than carcinogenicity. (from Lewis Dictionary of Toxicology, 1st ed)
The transference of BONE MARROW from one human or animal to another for a variety of purposes including HEMATOPOIETIC STEM CELL TRANSPLANTATION or MESENCHYMAL STEM CELL TRANSPLANTATION.
Oxygen-carrying RED BLOOD CELLS in mammalian blood that are abnormal in structure or function.
A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.
Transfer of HEMATOPOIETIC STEM CELLS from BONE MARROW or BLOOD between individuals within the same species (TRANSPLANTATION, HOMOLOGOUS) or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). Hematopoietic stem cell transplantation has been used as an alternative to BONE MARROW TRANSPLANTATION in the treatment of a variety of neoplasms.
The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.
A nucleoside antibiotic isolated from Streptomyces antibioticus. It has some antineoplastic properties and has broad spectrum activity against DNA viruses in cell cultures and significant antiviral activity against infections caused by a variety of viruses such as the herpes viruses, the VACCINIA VIRUS and varicella zoster virus.
Inorganic or organic compounds that contain the basic structure RB(OH)2.
The arrangement of two or more amino acid or base sequences from an organism or organisms in such a way as to align areas of the sequences sharing common properties. The degree of relatedness or homology between the sequences is predicted computationally or statistically based on weights assigned to the elements aligned between the sequences. This in turn can serve as a potential indicator of the genetic relatedness between the organisms.
The transfer of erythrocytes from a donor to a recipient or reinfusion to the donor.
Enlargement of the spleen.
Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others.
A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313)
A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen.
Levels within a diagnostic group which are established by various measurement criteria applied to the seriousness of a patient's disorder.
Studies in which subsets of a defined population are identified. These groups may or may not be exposed to factors hypothesized to influence the probability of the occurrence of a particular disease or other outcome. Cohorts are defined populations which, as a whole, are followed in an attempt to determine distinguishing subgroup characteristics.
A delayed response interval occurring when two stimuli are presented in close succession.
Transplantation of an individual's own tissue from one site to another site.
An infant during the first month after birth.
The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION.
Disorders of the blood and blood forming tissues.
Immature, nucleated ERYTHROCYTES occupying the stage of ERYTHROPOIESIS that follows formation of ERYTHROID PRECURSOR CELLS and precedes formation of RETICULOCYTES. The normal series is called normoblasts. Cells called MEGALOBLASTS are a pathologic series of erythroblasts.
The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.
The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment.
Diseases of plants.
Serum containing GAMMA-GLOBULINS which are antibodies for lymphocyte ANTIGENS. It is used both as a test for HISTOCOMPATIBILITY and therapeutically in TRANSPLANTATION.
Nucleosides containing arabinose as their sugar moiety.
The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.
Removal of bone marrow and evaluation of its histologic picture.
The number of WHITE BLOOD CELLS per unit volume in venous BLOOD. A differential leukocyte count measures the relative numbers of the different types of white cells.
The giving of drugs, chemicals, or other substances by mouth.
The senescence of RED BLOOD CELLS. Lacking the organelles that make protein synthesis possible, the mature erythrocyte is incapable of self-repair, reproduction, and carrying out certain functions performed by other cells. This limits the average life span of an erythrocyte to 120 days.
Transplantation between individuals of the same species. Usually refers to genetically disparate individuals in contradistinction to isogeneic transplantation for genetically identical individuals.
A nutritional condition produced by a deficiency of VITAMIN B 12 in the diet, characterized by megaloblastic anemia. Since vitamin B 12 is not present in plants, humans have obtained their supply from animal products, from multivitamin supplements in the form of pills, and as additives to food preparations. A wide variety of neuropsychiatric abnormalities is also seen in vitamin B 12 deficiency and appears to be due to an undefined defect involving myelin synthesis. (From Cecil Textbook of Medicine, 19th ed, p848)
A disorder characterized by reduced synthesis of the beta chains of hemoglobin. There is retardation of hemoglobin A synthesis in the heterozygous form (thalassemia minor), which is asymptomatic, while in the homozygous form (thalassemia major, Cooley's anemia, Mediterranean anemia, erythroblastic anemia), which can result in severe complications and even death, hemoglobin A synthesis is absent.
Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake.
BENZOIC ACID amides.
Mapping of the KARYOTYPE of a cell.
Surgical procedure involving either partial or entire removal of the spleen.
The worsening of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis.
A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
The development and formation of various types of BLOOD CELLS. Hematopoiesis can take place in the BONE MARROW (medullary) or outside the bone marrow (HEMATOPOIESIS, EXTRAMEDULLARY).
White blood cells formed in the body's lymphoid tissue. The nucleus is round or ovoid with coarse, irregularly clumped chromatin while the cytoplasm is typically pale blue with azurophilic (if any) granules. Most lymphocytes can be classified as either T or B (with subpopulations of each), or NATURAL KILLER CELLS.
A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)
Established cell cultures that have the potential to propagate indefinitely.
The rate dynamics in chemical or physical systems.
The number of PLATELETS per unit volume in a sample of venous BLOOD.
A genus in the family ORTHOMYXOVIRIDAE containing one species: Infectious salmon anemia virus.
A decrease in the number of NEUTROPHILS found in the blood.
A group of hereditary hemolytic anemias in which there is decreased synthesis of one or more hemoglobin polypeptide chains. There are several genetic types with clinical pictures ranging from barely detectable hematologic abnormality to severe and fatal anemia.
A multistage process that includes cloning, physical mapping, subcloning, determination of the DNA SEQUENCE, and information analysis.
Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen.
The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.
Death resulting from the presence of a disease in an individual, as shown by a single case report or a limited number of patients. This should be differentiated from DEATH, the physiological cessation of life and from MORTALITY, an epidemiological or statistical concept.
A weapon designed to explode when deployed. It frequently refers to a hollow case filled with EXPLOSIVE AGENTS.
A protozoan disease caused in humans by four species of the PLASMODIUM genus: PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM OVALE; and PLASMODIUM MALARIAE; and transmitted by the bite of an infected female mosquito of the genus ANOPHELES. Malaria is endemic in parts of Asia, Africa, Central and South America, Oceania, and certain Caribbean islands. It is characterized by extreme exhaustion associated with paroxysms of high FEVER; SWEATING; shaking CHILLS; and ANEMIA. Malaria in ANIMALS is caused by other species of plasmodia.
Diazo derivatives of aniline, used as a reagent for sugars, ketones, and aldehydes. (Dorland, 28th ed)
Persistent pain that is refractory to some or all forms of treatment.
The cells in the erythroid series derived from MYELOID PROGENITOR CELLS or from the bi-potential MEGAKARYOCYTE-ERYTHROID PROGENITOR CELLS which eventually give rise to mature RED BLOOD CELLS. The erythroid progenitor cells develop in two phases: erythroid burst-forming units (BFU-E) followed by erythroid colony-forming units (CFU-E); BFU-E differentiate into CFU-E on stimulation by ERYTHROPOIETIN, and then further differentiate into ERYTHROBLASTS when stimulated by other factors.
In vitro method for producing large amounts of specific DNA or RNA fragments of defined length and sequence from small amounts of short oligonucleotide flanking sequences (primers). The essential steps include thermal denaturation of the double-stranded target molecules, annealing of the primers to their complementary sequences, and extension of the annealed primers by enzymatic synthesis with DNA polymerase. The reaction is efficient, specific, and extremely sensitive. Uses for the reaction include disease diagnosis, detection of difficult-to-isolate pathogens, mutation analysis, genetic testing, DNA sequencing, and analyzing evolutionary relationships.
Process of classifying cells of the immune system based on structural and functional differences. The process is commonly used to analyze and sort T-lymphocytes into subsets based on CD antigens by the technique of flow cytometry.
Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely.
Leukocytes with abundant granules in the cytoplasm. They are divided into three groups according to the staining properties of the granules: neutrophilic, eosinophilic, and basophilic. Mature granulocytes are the NEUTROPHILS; EOSINOPHILS; and BASOPHILS.
Age as a constituent element or influence contributing to the production of a result. It may be applicable to the cause or the effect of a circumstance. It is used with human or animal concepts but should be differentiated from AGING, a physiological process, and TIME FACTORS which refers only to the passage of time.
Large, hoofed mammals of the family EQUIDAE. Horses are active day and night with most of the day spent seeking and consuming food. Feeding peaks occur in the early morning and late afternoon, and there are several daily periods of rest.
The major component of hemoglobin in the fetus. This HEMOGLOBIN has two alpha and two gamma polypeptide subunits in comparison to normal adult hemoglobin, which has two alpha and two beta polypeptide subunits. Fetal hemoglobin concentrations can be elevated (usually above 0.5%) in children and adults affected by LEUKEMIA and several types of ANEMIA.
A Fanconi anemia complementation group protein. It is an essential component of a nuclear core complex that protects the GENOME against CHROMOSOMAL INSTABILITY. It interacts directly with FANCG PROTEIN and helps stabilize a complex with FANCA PROTEIN and FANCC PROTEIN.
A cytologic technique for measuring the functional capacity of stem cells by assaying their activity.
RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.
A Fanconi anemia complementation group protein that interacts with FANCC PROTEIN and FANCD2 PROTEIN. It promotes the accumulation of FANCC protein in the CELL NUCLEUS.
An anti-inflammatory 9-fluoro-glucocorticoid.
Increased numbers of platelets in the peripheral blood. (Dorland, 27th ed)
The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION.
Conditions characterized by recurrent paroxysmal neuronal discharges which arise from a focal region of the brain. Partial seizures are divided into simple and complex, depending on whether consciousness is unaltered (simple partial seizure) or disturbed (complex partial seizure). Both types may feature a wide variety of motor, sensory, and autonomic symptoms. Partial seizures may be classified by associated clinical features or anatomic location of the seizure focus. A secondary generalized seizure refers to a partial seizure that spreads to involve the brain diffusely. (From Adams et al., Principles of Neurology, 6th ed, pp317)
A nutritional condition produced by a deficiency of FOLIC ACID in the diet. Many plant and animal tissues contain folic acid, abundant in green leafy vegetables, yeast, liver, and mushrooms but destroyed by long-term cooking. Alcohol interferes with its intermediate metabolism and absorption. Folic acid deficiency may develop in long-term anticonvulsant therapy or with use of oral contraceptives. This deficiency causes anemia, macrocytic anemia, and megaloblastic anemia. It is indistinguishable from vitamin B 12 deficiency in peripheral blood and bone marrow findings, but the neurologic lesions seen in B 12 deficiency do not occur. (Merck Manual, 16th ed)
A de novo myeloproliferation arising from an abnormal stem cell. It is characterized by the replacement of bone marrow by fibrous tissue, a process that is mediated by CYTOKINES arising from the abnormal clone.
An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.
A 67-kDa sialic acid binding lectin that is specific for MYELOID CELLS and MONOCYTE-MACROPHAGE PRECURSOR CELLS. This protein is the smallest siglec subtype and contains a single immunoglobulin C2-set domain. It may play a role in intracellular signaling via its interaction with SHP-1 PROTEIN-TYROSINE PHOSPHATASE and SHP-2 PROTEIN-TYROSINE PHOSPHATASE.
An orally administered anthracycline antineoplastic. The compound has shown activity against BREAST NEOPLASMS; LYMPHOMA; and LEUKEMIA.
An impulse-conducting system composed of modified cardiac muscle, having the power of spontaneous rhythmicity and conduction more highly developed than the rest of the heart.
An excessive accumulation of iron in the body due to a greater than normal absorption of iron from the gastrointestinal tract or from parenteral injection. This may arise from idiopathic hemochromatosis, excessive iron intake, chronic alcoholism, certain types of refractory anemia, or transfusional hemosiderosis. (From Churchill's Illustrated Medical Dictionary, 1989)
A cobalt-containing coordination compound produced by intestinal micro-organisms and found also in soil and water. Higher plants do not concentrate vitamin B 12 from the soil and so are a poor source of the substance as compared with animal tissues. INTRINSIC FACTOR is important for the assimilation of vitamin B 12.
Progressive restriction of the developmental potential and increasing specialization of function that leads to the formation of specialized cells, tissues, and organs.
Translation products of a fusion gene derived from CHROMOSOMAL TRANSLOCATION of C-ABL GENES to the genetic locus of the breakpoint cluster region gene on chromosome 22. Several different variants of the bcr-abl fusion proteins occur depending upon the precise location of the chromosomal breakpoint. These variants can be associated with distinct subtypes of leukemias such as PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; and NEUTROPHILIC LEUKEMIA, CHRONIC.
A compound suggested to be both a nootropic and a neuroprotective agent.
One of the mechanisms by which CELL DEATH occurs (compare with NECROSIS and AUTOPHAGOCYTOSIS). Apoptosis is the mechanism responsible for the physiological deletion of cells and appears to be intrinsically programmed. It is characterized by distinctive morphologic changes in the nucleus and cytoplasm, chromatin cleavage at regularly spaced sites, and the endonucleolytic cleavage of genomic DNA; (DNA FRAGMENTATION); at internucleosomal sites. This mode of cell death serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth.
Naturally occurring or experimentally induced animal diseases with pathological processes sufficiently similar to those of human diseases. They are used as study models for human diseases.
Immature ERYTHROCYTES. In humans, these are ERYTHROID CELLS that have just undergone extrusion of their CELL NUCLEUS. They still contain some organelles that gradually decrease in number as the cells mature. RIBOSOMES are last to disappear. Certain staining techniques cause components of the ribosomes to precipitate into characteristic "reticulum" (not the same as the ENDOPLASMIC RETICULUM), hence the name reticulocytes.
The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065)
A glycoprotein of MW 25 kDa containing internal disulfide bonds. It induces the survival, proliferation, and differentiation of neutrophilic granulocyte precursor cells and functionally activates mature blood neutrophils. Among the family of colony-stimulating factors, G-CSF is the most potent inducer of terminal differentiation to granulocytes and macrophages of leukemic myeloid cell lines.
Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION.
Thrombocytopenia occurring in the absence of toxic exposure or a disease associated with decreased platelets. It is mediated by immune mechanisms, in most cases IMMUNOGLOBULIN G autoantibodies which attach to platelets and subsequently undergo destruction by macrophages. The disease is seen in acute (affecting children) and chronic (adult) forms.
Membrane glycoproteins found in high concentrations on iron-utilizing cells. They specifically bind iron-bearing transferrin, are endocytosed with its ligand and then returned to the cell surface where transferrin without its iron is released.
Inorganic or organic compounds that contain divalent iron.
A cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes. It is used for the prophylaxis of graft rejection in organ and tissue transplantation. (From Martindale, The Extra Pharmacopoeia, 30th ed).
Sequential operating programs and data which instruct the functioning of a digital computer.
Biologically active substances whose activities affect or play a role in the functioning of the immune system.

Human herpes virus-6 seroprevalence and leukaemias: a case-control study. GIMEMA (Gruppo Italiano Malattie Ematologiche dell' Adulto). (1/109)

The relationships between acute myeloid leukaemia (AML), acute lymphocytic leukaemia (ALL), chronic myeloid leukaemia (CML) and refractory anaemia with excess of blasts (RAEB) and human herpes virus (HHV)-6 antibody level were investigated in a multicentre case-control study. An association between increased HHV-6 seropositivity and geometric mean titre ratio with AML was shown: P for trend = 0.022, adjusted odds ratio 1.20, 95% confidence interval 1.07-1.33 respectively. No association was found between HHV-6 and ALL, CML or RAEB.  (+info)

A new recurrent translocation, t(5;11)(q35;p15.5), associated with del(5q) in childhood acute myeloid leukemia. The UK Cancer Cytogenetics Group (UKCCG) (2/109)

Partial deletion of the long arm of chromosome 5, del(5q), is the cytogenetic hallmark of the 5q-syndrome, a distinct subtype of myelodysplastic syndrome-refractory anemia (MDS-RA). Deletions of 5q also occur in the full spectrum of other de novo and therapy-related MDS and acute myeloid leukemia (AML) types, most often in association with other chromosome abnormalities. However, the loss of genetic material from 5q is believed to be of primary importance in the pathogenesis of all del(5q) disorders. In the present study, we performed fluorescence in situ hybridization (FISH) studies using a chromosome 5-specific whole chromosome painting probe and a 5q subtelomeric probe to determine the incidence of cryptic translocations. We studied archival fixed chromosome suspensions from 36 patients with myeloid disorders (predominantly MDS and AML) and del(5q) as the sole abnormality. In 3 AML patients studied, this identified a translocation of 5q subtelomeric sequences from the del(5q) to the short arm of an apparently normal chromosome 11. FISH with chromosome 11-specific subtelomeric probes confirmed the presence of 11p on the shortened 5q. Further FISH mapping confirmed that the 5q and 11p translocation breakpoints were the same in all 3 cases, between the nucleophosmin (NPM1) and fms-related tyrosine kinase 4 (FLT4) genes on 5q35 and the Harvey ras-1-related gene complex (HRC) and the radixin pseudogene (RDPX1) on 11p15.5. Importantly, all 3 patients with the cryptic t(5;11) were children: a total of 3 of 4 AML children studied. Two were classified as AML-M2 and the third was classified as M4. All 3 responded poorly to treatment and had short survival times, ranging from 10 to 18 months. Although del(5q) is rare in childhood AML, this study indicates that, within this subgroup, the incidence of cryptic t(5;11) may be high. It is significant that none of the 24 MDS patients studied, including 11 confirmed as having 5q-syndrome, had the translocation. Therefore, this appears to be a new nonrandom chromosomal translocation, specifically associated with childhood AML with a differentiated blast cell phenotype and the presence of a del(5q).  (+info)

Prognostic significance of magnetic resonance imaging of femoral marrow in patients with myelodysplastic syndromes. (3/109)

PURPOSE: To investigate whether the abnormalities observed on femoral marrow magnetic resonance images are related to the development of leukemia and survival of patients with myelodysplastic syndromes (MDS). PATIENTS AND METHODS: The findings on magnetic resonance images of the femoral marrow were evaluated over periods of 1 to 92 months (median, 18 months) in 42 consecutive adult patients with newly diagnosed MDS. Magnetic resonance images were obtained by the T1-weighted spin echo method and the short T1 inversion recovery technique. RESULTS: Magnetic resonance images showed that the femoral marrow patterns changed from fatty, faint, or nodular to scattered or uniform as the disease progressed. Development of acute myeloid leukemia was observed in only 13 patients whose marrow exhibited a scattered or uniform pattern. The overall survival of the 29 patients with a scattered or uniform marrow pattern was significantly shorter than that of the 13 patients with a fatty, faint, or nodular marrow pattern (10.7% v 73.3% at 7 years; P < .01). The period of leukemia-free survival was also significantly shorter in the patients with a scattered or uniform marrow pattern versus a fatty, faint, or nodular pattern (37.7% v 100% at 7 years; P < .01). CONCLUSION: Magnetic resonance images of the femoral marrow can provide valuable information for assessing the prognosis and determining the most appropriate management of patients with MDS.  (+info)

Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia. (4/109)

PURPOSE: To evaluate the efficacy and safety of the combination of topotecan and cytarabine in patients with myelodysplastic syndromes (MDSs) and chronic myelomonocytic leukemia (CMML). PATIENTS AND METHODS: Fifty-nine patients with MDSs and 27 with CMML were enrolled. They were either previously untreated (66%) or had received only biologic agents (14%) or chemotherapy with or without biologic agents (20%). Treatment consisted of topotecan 1.25 mg/m(2) by continuous intravenous infusion daily for 5 days and cytarabine 1. 0 g/m(2) by infusion over 2 hours daily for 5 days. Prophylaxis included antibacterial, antifungal, and antiviral agents. At a median follow-up of 7 months, all 86 patients were assessable for response and toxicity. RESULTS: Complete remission (CR) was observed in 48 patients (56%; 61% with MDSs, 44% with CMML; P =.15). Similar CR rates were observed for patients with good-risk and poor-risk MDS (70% and 56%, respectively). The treatment effectively induced CR in patients with a poor-prognosis karyotype involving chromosomes 5 and 7 (CR, 71%) and secondary MDSs (CR, 72%). Fifty-four patients received one induction course, 25 patients received two, and the rest received more than two. The median number of continuation courses was two. The median overall duration of CR was 34 weeks (50 weeks for MDSs and 33 weeks for CMML). The median survival was 60 weeks for MDS and 44 weeks for CMML patients. CR and survival durations were longer in patients with refractory anemia with excess blasts (RAEB). Grade 3 or 4 mucositis or diarrhea was observed in three patients each. Fever was observed in 63%, and infections in 49% of patients. Six patients (7%) died during induction therapy. CONCLUSION: Topotecan and cytarabine induced high CR rates in unselected patients with MDSs and CMML, particularly among patients with poor-prognosis cytogenetics and secondary MDSs. Topotecan-cytarabine is an active induction regimen in MDS and CMML patients, is well tolerated, and is associated with a low mortality rate.  (+info)

Effect of time to complete remission on subsequent survival and disease-free survival time in AML, RAEB-t, and RAEB. (5/109)

The authors examined the relationship between the time required to enter complete remission (CR) after a first course of chemotherapy for newly diagnosed acute myeloid leukemia (AML), refractory anemia with excess blasts in transformation (RAEB-t), or refractory anemia with excess blasts (RAEB). They also examined subsequent survival time and disease-free survival time after accounting for cytogenetic status, age, and treatment. The data set consisted of 1101 patients with these diagnoses treated at the M. D. Anderson Cancer Center between 1980 and 1996 for whom outcomes were established after first-course therapy. Of the 1101 patients, 740 (67%) were in CR after this time; 508 of these 740 (69%) have died (80% had disease recurrence before death). The authors used the parametric model of Shen and Thall to estimate, in particular, T(C) (time to CR), T(C,D) (time from CR to death = residual survival after CR), and T(C,R) (residual disease-free survival [DFS] after CR) as functions of the covariates noted above and to estimate the dependence of T(C,D) and T(C,R) on T(C). There was a strong inverse association between T(C) and both T(C,D) and T(C,R) (P <.001 for both) that was independent of cytogenetic status, age, or treatment. The residual survival time of patients who required >50 days to enter CR was closer to the residual survival time of resistant patients than to that of patients known to be in CR within approximately 30 days of the start of treatment. Time to CR is an independent predictor of residual survival and disease-free survival in patients with newly diagnosed AML who achieve CR after 1 course of chemotherapy. (Blood. 2000;95:72-77)  (+info)

Successful peripheral blood stem cell transplantation for myelodysplastic syndrome. (6/109)

Wilms' tumor (WT1) gene expression is increased in patients with leukemia as well as myelodysplastic syndrome (MDS) and is useful for detection of minimal residual disease (MRD). A 47-year-old man given a diagnosis of refractory anemia with excess of blasts in transformation (RAEB-T) received myeloablative therapy followed by autologous peripheral blood stem cell transplantation (PBSCT). MRD by WT1 expression was not detected in the graft. The patient has been in CR for 25 months after PBSCT. These observations suggest that PBSCT is feasible for patients with RAEB-T and analysis of WT1 expression can be applied for patients with high risk MDS.  (+info)

Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age. (7/109)

We carried out bone marrow transplantation (BMT) in 50 patients with myelodysplastic syndrome (MDS) who were 55.3 to 66.2 years of age (median, 58.8 years). According to the criteria of the French-American-British (FAB) classification, 13 patients had refractory anemia (RA), 19 had RA with excess blasts (RAEB), 16 had RAEB in transformation or acute myelogenous leukemia (RAEB-T/AML), and 2 had chronic myelomonocytic leukemia (CMML). According to the recently established International Prognostic Scoring System (IPSS), available for 45 patients, 2 patients were considered low risk; 14, intermediate 1 risk; 19, intermediate 2 risk; and 10, high risk. Conditioning regimens were cyclophosphamide (CY) (120 mg/kg of body weight) plus 12-Gy fractionated total-body irradiation (FTBI) (n = 15), CY plus FTBI with lung and liver shielding (n = 4), busulfan (7 mg/kg) plus FTBI (n = 4), or busulfan (16 mg/kg) plus CY (n = 27). The busulfan-plus-CY group included 16 patients in whom busulfan was targeted to plasma levels of 600 to 900 ng/mL. In these 16 patients, steady-state levels of busulfan actually achieved were 714 to 961 ng/mL (mean +/- SD, 845 +/- 64 ng/mL; median, 838 ng/mL). The donors were HLA-identical siblings for 34 patients, HLA-nonidentical family members for 4, identical twins for 4, and unrelated volunteers for 6. All 46 patients surviving > 21 days had engraftment, and 22 patients (44%) are surviving 9 to 80 months after BMT. Specifically, among 13 patients with RA, 1 had relapse (cumulative incidence [CI] at 3 years, 8%) and 8 are surviving, for a Kaplan-Meier (KM) estimate of survival at 3 years of 59% (disease-free survival [DSF], 53%). Among 19 patients with RAEB, 3 had relapse (CI at 3 years, 16%), and 8 are surviving disease free (KM estimate at 3 years, 46%). Among 18 patients with RAEB-T/AML or CMML, 6 had relapse (CI at 3 years, 28%), and the KM estimate of DSF at 3 years is 33%. Relapse-free survival had an inverse correlation with cytogenetic risk classification and with the risk score according to the IPSS. Survival in all FAB categories was highest among patients enrolled in a protocol in which busulfan plasma levels were targeted to 600 to 900 ng/mL. These data indicate that BMT can be carried out successfully in patients with MDS who are older than 55 years of age. (Blood. 2000;95:1188-1194)  (+info)

Deletions of chromosome 5q13.3 and 17p loci cooperate in myeloid neoplasms. (8/109)

Nonrandom interstitial deletions and monosomy of chromosomes 5, 7, and 17 in refractory myelodysplasia (MDS) and acute myelogenous leukemia (AML) suggest a multistep pathway that culminates in aggressive clinical course. Because cytogenetic studies frequently identify chromosome 5 and 17 deletions within a single clone, we searched for allele loss for 5q loci and TP53 gene mutations in the same leukemic samples. Cosegregating deletions of chromosomes 5 and 17 were found to specifically include the 5q13.3 interval between the loci D5S672 and D5S620/D5S626, a locus hypothesized to harbor a tumor suppressor gene(1) and the TP53 gene on 17p. A rare patient with secondary refractory MDS and an unbalanced translocation [der(5;17)], which resulted in deletions of the 5q13.3-qter and 17p loci, provided clues on the sequence of genetic alterations. Serial molecular analysis of this patient revealed a dysplastic clone with der(5;17), which gave rise to a leukemic clone on acquiring an inactivating mutation of TP53. Our findings are consistent with functional cooperation between a putative tumor suppressor gene at 5q13.3 that contributes toward the progression of early stages of MDS, and the TP53 gene when mutated, causes transformation to AML. (Blood. 2000;95:2138-2143)  (+info)

OBJECTIVES:. I. Determine the maximum tolerated dose of vorinostat (SAHA) when given in combination with flavopiridol (alvocidib) in patients with advanced solid tumors.. II. Obtain preliminary data on the therapeutic activity of SAHA and flavopiridol in these patients.. III. Evaluate the role of p21, p53, and apoptotic markers relative to treatment response in patients treated with this regimen.. OUTLINE: This is a multicenter, open label, non-randomized, dose-escalation study of vorinostat (SAHA).. Before beginning course 1 of study therapy, patients receive oral SAHA on days 1-3 in order to ensure tolerability of the drug. Beginning 1 week later, patients receive oral SAHA once daily on days 1-3 and 8-10 and fixed-dose alvocidib intravenously (IV) over 1 hour on days 2 and 9. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.. Cohorts of 3-6 patients receive escalating doses of SAHA until the maximum tolerated dose (MTD) is determined. The MTD is ...
OBJECTIVES:. I. Determine the maximum tolerated dose of vorinostat (SAHA) when given in combination with flavopiridol (alvocidib) in patients with advanced solid tumors.. II. Obtain preliminary data on the therapeutic activity of SAHA and flavopiridol in these patients.. III. Evaluate the role of p21, p53, and apoptotic markers relative to treatment response in patients treated with this regimen.. OUTLINE: This is a multicenter, open label, non-randomized, dose-escalation study of vorinostat (SAHA).. Before beginning course 1 of study therapy, patients receive oral SAHA on days 1-3 in order to ensure tolerability of the drug. Beginning 1 week later, patients receive oral SAHA once daily on days 1-3 and 8-10 and fixed-dose alvocidib intravenously (IV) over 1 hour on days 2 and 9. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.. Cohorts of 3-6 patients receive escalating doses of SAHA until the maximum tolerated dose (MTD) is determined. The MTD is ...
[RAEB in transformation in continuing complete remission by small doses of cytarabin]. - T Yamada, N Sueoka, Y Tanabe, K Dan, S Kuriya, T Nomura, T Shiomura
Alvocidib is a synthetic flavonoid based on an extract from an Indian plant for the potential treatment of cancer. It works by inhibiting cyclin-dependent kinases, arresting cell division and causing apoptosis in non-small lung cancer cells.
Learn in-depth information on Refractory Anemia with Excess Blasts, its causes, symptoms, diagnosis, complications, treatment, prevention, and prognosis.
Immunohistochemistry has become a very important, and in some cases indispensable, tool in diagnostic pathology, enabling the precise identification of tumours, the detection of micrometastases in a given sample, and the evaluation of various prognosis factors. However, in some cases, the use of multiple but distinct immunostains can lead to some unforeseen results-for example, the expression of an apparently aberrant marker by a neoplasm can sometimes be seen. In this context, we report our experience with a case of refractory anaemia with excess of blasts in transformation (RAEB-t) in which the blasts were unexpectedly found to express cytokeratin (CK).. An 86 year old woman with a past medical history of breast carcinoma treated by mastectomy and adjuvant radiotherapy was admitted to our institution because of worsening anaemia. The following haematological indices were noticed: haemoglobin, 8.6 g/litre; erythrocytes, 2.5 × 1012/litre; white blood cells, 3 × 109/litre; and platelets, 465 × ...
Question - Refractory anaemia,very low counts,works as a builder,has pacemaker,ulcerated leg after fall,treatment and prognosis?. Ask a Doctor about Blood transfusion, Ask a General & Family Physician
Because of the diversity of clinical symptoms, the diagnosis of mitochondrial DNA (mtDNA) deletion disorders can be difficult. Here, we describe an 8-month-old boy presenting clinically exclusively with refractory anemia. Mutation analysis in our pat
The primary objective of this study is to compare overall survival (OS) in patients receiving ON 01910.Na + best supportive care (BSC) to OS of patients
Patients. We searched the AML database for patients who presented to The University of Texas M. D. Anderson Cancer Center with newly diagnosed AML (≥20% myeloblasts) from 1990 through 2005. This database includes consecutive patients with AML or MDS seen at M. D. Anderson in the Department of Leukemia since 1985. Patients previously classified with refractory anemia with excess blasts in transformation were reclassified as AML. A total of 2,014 patients were identified, and pretreatment levels of β2M were available in 64% (i.e., 1,293 patients). Serum β2M levels were quantified by RIA (Pharmacia β-2 Micro Ria; Pharmacia Diagnostic; reference range, 0.7-2.0 mg/L). Treatment for AML varied during the 16 years depicted here, and for convenience we divided the patients into those who were given 1-β-d-arabinofuranosylcytosine (ara-C) and those who were not. All patients included in the prognostic models received remission induction therapy with high-dose ara-C, defined as ,0.5 g daily for 3 to ...
Vous tentez peut-être daccéder à ce site à partir dun navigateur sécurisé sur le serveur. Activez les scripts et rechargez la page ...
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day ...
Garcia-Manero G, Roboz G, Walsh K, Kantarjian H, Ritchie E, Kropf P, OConnell C, Tibes R, Lunin S, Rosenblat T, Yee K, Stock W, Griffiths E, Mace J, Podoltsev N, Berdeja J, Jabbour E, Issa JJ, Hao Y, Keer HN, Azab M, Savona MR. Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial. Lancet Haematol. 2019 Jun; 6(6):e317-e327 ...
Instantly find & access educational materials and complete eLearning activities at your leisure. Native iPad/iPhone/Android Apps are available for the convenience of on-the-go users.
Looking for online definition of refractory anemia with excess blasts in the Medical Dictionary? refractory anemia with excess blasts explanation free. What is refractory anemia with excess blasts? Meaning of refractory anemia with excess blasts medical term. What does refractory anemia with excess blasts mean?
MGI Pharma, Inc, and SuperGen, Inc, recently announced that the US Food and Drug Administration (FDA) has approved the hypomethylating agent decitabine (Dacogen) for injection. Decitabine is indicated for treatment of patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo, and secondary MDS of all French-American-British (FAB) subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia), and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System (IPSS) groups. 1
in Blood (1998), 92(1), 68-75. Treatment with erythropoietin (epo) may improve the anemia of myelodysplastic syndromes (MDS) in approximately 20% of patients. Previous studies have suggested that treatment with the combination of ... [more ▼]. Treatment with erythropoietin (epo) may improve the anemia of myelodysplastic syndromes (MDS) in approximately 20% of patients. Previous studies have suggested that treatment with the combination of granulocyte colony-stimulating factor (G-CSF) and epo may increase this response rate. In the present phase II study, patients with MDS and anemia were randomized to treatment with G-CSF + epo according to one of two alternatives; arm A starting with G-CSF for 4 weeks followed by the combination for 12 weeks, and arm B starting with epo for 8 weeks followed by the combination for 10 weeks. Fifty evaluable patients (10 refractory anemia [RA], 13 refractory anemia with ring sideroblasts [RARS], and 27 refractory anemia with excess blasts [RAEB]) were included ...
Refractory Anaemia (RA) is part of the heterogeneous group of diseases that affects normal blood cell production in the bone marrow and a category of myelodysplastic syndrome (MDS) . One example of RA is the 5q-syndrome. In RA, marrow blood cells fail to mature properly and are unable to work properly. They often die before they leave the marrow, or shortly after reaching the bloodstream (ineffective erythropoiesis or dyserythropoiesis). There are few data on the epidemiology of RA, which may account for 30-40% of all MDS cases. MDS is predominantly diagnosed in the elderly population. The global incidence of all MDS was comprised between 3,5 and 12,6 new cases / year / per 100,000 in some studies. ...
The British Society for Haematology is registered in England and Wales as a Company Limited by Guarantee, No 2645706 and as a Charity, No 1005735 Registered Office and correspondence address: 100 White Lion Street London N1 9PF. Phone: 020 7713 0990 ...
The gene IL-3 encodes interleukin 3, a hematopoietic colony-stimulating factor (CSF) that is capable of supporting the proliferation of a broad range of hematopoietic cell types. By using somatic cell hybrids and in situ chromosomal hybridization, we localized this gene to human chromosome 5 at bands q23-31, a chromosomal region that is frequently deleted [del(5q)] in patients with myeloid disorders. By in situ hybridization, IL-3 was found to be deleted in the 5q-chromosome of one patient with refractory anemia who had a del(5)(q15q33.3), of three patients with refractory anemia (two patients) or acute nonlymphocytic leukemia (ANLL) de novo who had a similar distal breakpoint [del(5)(q13q33.3)], and of a fifth patient, with therapy-related ANLL, who had a similar distal breakpoint in band q33 [del(5)(q14q33.3)]. Southern blot analysis of somatic cell hybrids retaining the normal or the deleted chromosome 5 from two patients with the refractory anemia 5q- syndrome indicated that IL-3 sequences were
The FDA has granted orphan drug designation to Alvocidib (flavopiridol) to treat patients with acute myeloid leukemia. Alvocidib, a potent c...
Median survival of RA may fall in the 27-50 month range. As noted above, heterogeneity of patient population may account for inter-study variability in median survival. The best outcome is usually observed in RA with isolated 5q- (5q- syndrome of the WHO classification) and in those patients without multilineage dysplasia, corresponding to the RA category in the WHO classification. Chromosomal abnormalities have independent prognostic significance and are to be included in risk assessment at diagnosis. Favourable cytogenetic features are normal karyotype, 5q- or 20q- isolated; unfavourable features are complex karyotype (i.e. 3 or more clonal anomalies) and abnormalities of chromosome 7q; other abnormalities identify patients in the intermediate cytogenetic-risk group.. ...
Free, official coding info for 2020 ICD-10-CM D46.20 - includes detailed rules, notes, synonyms, ICD-9-CM conversion, index and annotation crosswalks, DRG grouping and more.
Get online consultation for best treatment of Myelodysplastic Syndrome (MDS), Get a free 2nd opinion on Your Medical Problem, connect to the best doctors and hospitals for Myelodysplastic Syndrome (MDS) Treatment cost in India, Save upto 70-80% on cost of your treatment. ihealthkonnect
FYI - According to a recent article in the Journal of Clinical Oncology re: myelodysplastic syndromes (MDS): April 30, 2010 - Myelodysplastic syndromes (MDS) appear to be nearly 5 times more common...
Find the best myelodysplastic syndrome doctors in Delhi NCR. Get guidance from medical experts to select myelodysplastic syndrome specialist in Delhi NCR from trusted hospitals - credihealth.com
TY - JOUR. T1 - NPM1 gene deletions in myelodysplastic syndromes with 5q- and complex karyotype. AU - Ammatuna, Emanuele. AU - Panetta, Paola. AU - Agirre, Xabier. AU - Ottone, Tiziana. AU - Lavorgna, Serena. AU - Calasanz, Maria José. AU - Lo-Coco, Francesco. PY - 2011/5. Y1 - 2011/5. KW - 5q-. KW - Myelodysplastic syndromes. KW - Npm1 deletions. UR - http://www.scopus.com/inward/record.url?scp=79955738486&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=79955738486&partnerID=8YFLogxK. U2 - 10.3324/haematol.2010.038620. DO - 10.3324/haematol.2010.038620. M3 - Article. C2 - 21393327. AN - SCOPUS:79955738486. VL - 96. SP - 784. JO - Haematologica. JF - Haematologica. SN - 0390-6078. IS - 5. ER - ...
This trial is investigating the efficacy and tolerability of azacitidine in patients with intermediate-2 and high-risk myelodysplastic syndromes.
Learn more about Managing the Side Effects of Myelodysplastic Syndrome (MDS) and MDS Treatment at Doctors Hospital of Augusta Main Page ...
The myelodysplastic syndromes (MDS) encompass a series of hematologic conditions characterized by chronic cytopenias (anemia, neutropenia, thrombocytopenia) accompanied by abnormal cellular maturation. As a result, patients with MDS are at risk for s
For more videos by Vernon Louw MedEd, go to: http://www.youtube.com/user/Legomed/videos?view_as=public This video explains the natural course of disease in patients with MDS and the principles ...
Learn more about Cancer In Depth: Myelodysplastic Syndrome (MDS) at Coliseum Health System Main Page Risk Factors ...
Learn more about Other Treatments for Myelodysplastic Syndrome (MDS) at Grand Strand Medical Center Main Page Risk Factors ...
Characteristic features of myelodysplastic syndrome (MDS) in humans. MDS is thought to originate from a mutated Hematopoietic stem cell (HSC). Approximately 30%
The long-term goal of this project is to identify and characterize genes that contribute to the development and progression of myelodysplastic syndromes (MDS)....
For more videos by Vernon Louw MedEd, go to: http://www.youtube.com/user/Legomed/videos?view_as=public This video explains the natural course of disease in patients with MDS and the principles ...
Drs. Scott and Estey provide an excellent, concise review of current diagnostic and therapeutic approaches for patients with myelodysplastic syndromes (MDS). Both physicians are recognized world leaders in this area.
The purpose of this study is to determine the overall response rate in patients with myelodysplastic syndromes (MDS) given a daily dosing schedule of de
Knowing what to expect if you have MDS can help. Learn about myelodysplastic syndromes, including risk factors, symptoms, diagnosis, and treatment.
Here is some information from The Ohio State University Comprehensive Cancer Center - (OSUCCC - James) I wanted to share with you.
Learn more about Myelodysplastic Syndromes at Grand Strand Medical Center DefinitionCausesRisk FactorsSymptomsDiagnosisTreatmentPreventionrevision ...
Stevenson, W. and Garcia-Manero, G. (2010) Myelodysplastic Syndromes, in Leukemias: Principles and Practice of Therapy (eds S. Faderl and H. Kantarjian), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781444327359.ch8 ...
Rigosertib has been used in trials studying the treatment and basic science of MDS, RAEB, Cancer, Hepatoma, and Neoplasms, among others.
Deletion 5q is a rare form of Myeldysplastic Syndrome (MDS) which can remain stable for many years with few symptoms, or progress rapidly into a different MDS subtype.
Selected genes are highlighted in orange, bookmarked genes are green. - Chemical increases gene, - Chemical decreases gene, - Chemical increases and decreases gene simultaneosly, No arrows - gene doesnt interact with the chemical. - Gene should be increased/decreased most of the time and the chemical does it. - Gene should be increased/decreased most of the time but the chemical does the opposite. ...
I had been ill for sometime and when I went to hospital, the blood test showed something wrong, then a spinal tap was done and that confirmed it. I had chemo first and have had rituximab off and o ...
Do you want to buy Arctic Blast Review? Wait and read this Arctic Blast Review to find out its ingredients, benefits and side effects before you buy it.
This scalping system is extremely flexible. We have tested only a fraction of possible variations. Due to its versatile nature, it can be applied both as a sca
... bone marrow of patients with myelodysplastic syndromes with the highest expression in refractory anemia with excess of blasts ...
Refractory anemia. *Refractory anemia with excess of blasts. *Chromosome 5q deletion syndrome ... In order to fulfill World Health Organization (WHO) criteria for AML-5, a patient must have greater than 20% blasts in the bone ... blasts). Monoblasts can be distinguished by having a roughly circular nucleus, delicate lacy chromatin, and abundant, often ...
Blast furnace processing. Main article: Blast furnace. The blast furnace is loaded with iron ores, usually hematite Fe. 2O. 3 ... "Iron Deficiency Anemia". MediResource. Retrieved 17 December 2008.. *^ Milman, N. (1996). "Serum ferritin in Danes: studies of ... Excess. Main article: Iron overload. Iron uptake is tightly regulated by the human body, which has no regulated physiological ... and the most common refractory element.[24] ... Medieval blast furnaces were about 10 feet (3.0 m) tall and ...
Refractory anemia. *Refractory anemia with excess of blasts. *Chromosome 5q deletion syndrome ... Moreover, it inhibits DNA repair, causing genomic instability and potentially causing the feared blast crisis in CML. ... "blast crisis".[citation needed] In 2000 Dr. John Kuriyan determined the mechanism by which STI-571 inhibits the Abl kinase ...
Refractory anemia. *Refractory anemia with excess of blasts. *Chromosome 5q deletion syndrome ... Excess gastric acid can harm the stomach, esophagus, and small intestine.. *Epinephrine constricts blood vessels and opens ...
Refractory anemia. *Refractory anemia with excess of blasts. *Chromosome 5q deletion syndrome ... Blasts affected by the disease may come together and become swollen in the liver or in the lymph nodes causing pain and leading ... Finally, the red blood cell deficiency leads to anemia, which may cause dyspnea and pallor. ... and Fanconi anemia is a risk factor for developing acute myeloid leukemia.[35] Mutation in SPRED1 gene has been associated with ...
Refractory anemia. *Refractory anemia with excess of blasts. *Chromosome 5q deletion syndrome ... The goal of treatment for MF is amelioration of anemia, splenomegaly, and other symptoms. Low-dose aspirin is effective in PV ... are a group of diseases of the bone marrow in which excess cells are produced. They are related to, and may evolve into, ...
... refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) ... Refractory anemia with excess of blasts (RAEB) is a type of myelodysplastic syndrome with a marrow blast percentage of 5% to 19 ... July 2006). "An antecedent diagnosis of refractory anemia with excess blasts has no prognostic relevance in acute myeloid ...
... refractory anaemia with ring sideroblasts, refractory anaemia with excess blasts and refractory anaemia with excess blasts in ... It placed CMML into the category of MDS, along with the refractory anaemia, ... The FAB criteria for diagnosis are as follows: Monocyte count >1x109/L 0-19% blasts in bone marrow 1x109/L No Philadelphia ... In CMML, there are increased numbers of monocytes and immature blood cells (blasts) in the peripheral blood and bone marrow, as ...
... anemia M9982/3 Refractory anemia with ringed sideroblasts with sideroblasts M9983/3 Refractory anemia with excess blasts RAEB ... NOS Blast cell leukemia Undifferentiated leukemia Stem cell leukemia M9805/3 Acute biphenotypic leukemia Acute leukemia of ... RAEB I RAEB II M9985/3 Refractory cytopenia with multilineage dysplasia M9986/3 Myelodysplastic syndrome associated with ... unclassifiable M9980/3 Chronic myelomonocytic leukemia or Refractory ...
Three forms exist and include refractory anemia with ringed sideroblasts (RARS), refractory anemia with ringed sideroblasts and ... Excess zinc can indirectly cause sideroblastic anemia by decreasing absorption and increasing excretion of copper. ... blast) are nucleated erythroblasts (precursors to mature red blood cells) with granules of iron accumulated in the mitochondria ... Sideroblastic anemia, or sideroachrestic anemia, is a form of anemia in which the bone marrow produces ringed sideroblasts ...
... refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in ...
Two patients with refractory anemia with excess of blasts in transformation having entered remission and in continuing complete ... Anemia, Refractory, with Excess of Blasts (drug therapy) *Cytarabine (administration & dosage, therapeutic use) ...
... refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) ... Refractory anemia with excess of blasts (RAEB) is a type of myelodysplastic syndrome with a marrow blast percentage of 5% to 19 ... July 2006). "An antecedent diagnosis of refractory anemia with excess blasts has no prognostic relevance in acute myeloid ...
2018 Refractory Anemia with Excess Blasts Global Clinical Trials Review, H1, 2018 Summary GlobalDatas clinical trial report ... Refractory Anemia with Excess Blasts Global Clinical Trials Review, H1, ... Proportion of Refractory Anemia With Excess Blasts to Oncology Clinical Trials*Table Figure 8: Proportion of Refractory Anemia ... "Refractory Anemia with Excess Blasts Global Clinical Trials Review, H1, 2018 provides an overview of Refractory Anemia With ...
RAEB/t stands for refractory anemia with excess blasts-transformation. RAEB/t is defined as refractory anemia with excess ... How is refractory anemia with excess blasts-transformation abbreviated? ... www.acronymattic.com/refractory-anemia-with-excess-blasts_transformation-(RAEB%2ft).html,RAEB/t,/a,. ... www.acronymattic.com/refractory-anemia-with-excess-blasts_transformation-(RAEB%2ft).html ...
Refractory Anemia with Excess of Blasts (RAEM). 1/2013. Immunophenotyping in myelodysplastic syndromes can add prognostic ... Sickle Cell Anemia (Hemoglobin S Disease) 01/2005. Drug/Important Bio-Agent (IBA). 4. imatinib (Gleevec)FDA Link 08/2015 - 01/ ... Refractory Anemia with Excess of Blasts (RAEM) 01/2013 - 02/2004. 4. Sepsis (Septicemia) 01/2013 - 01/2010. ...
Refractory anemia with excess blasts in transformation / Acute myeloblastic leukemia, minimal differentiation / Refractory ... DBCOND0028567 (Refractory Anemia With Excess Blasts in Transformation). Completed. 1 / 2. clinicaltrials.gov Identifier. Title ... Refractory Anemia With Excess Blasts in Transformation Completed Phase 1 / 2 Trials for Idarubicin (DB01177). Back to ...
The British Society for Haematology is registered in England and Wales as a Company Limited by Guarantee, No 2645706 and as a Charity, No 1005735 Registered Office and correspondence address: 100 White Lion Street London N1 9PF. Phone: 020 7713 0990 ...
Refractory anemia with excess blasts in transformation / Acute myeloblastic leukemia, minimal differentiation / Refractory ... Refractory Anemia With Excess Blasts in Transformation Active Not Recruiting Phase 2 Trials for Cyclophosphamide (DB00531). ... DBCOND0028567 (Refractory Anemia With Excess Blasts in Transformation). Active Not Recruiting. 2. ... Back to Refractory Anemia With Excess Blasts in Transformation. Also known as: ...
... refractory anemia with excess blasts explanation free. What is refractory anemia with excess blasts? Meaning of refractory ... anemia with excess blasts medical term. What does refractory anemia with excess blasts mean? ... Looking for online definition of refractory anemia with excess blasts in the Medical Dictionary? ... refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and refractory anemia with excess blasts in ...
Refractory anemia with excess of blasts, unspecified. 2016 2017 2018 2019 2020 Billable/Specific Code *D46.20 is a billable/ ... Refractory anemia with excess blasts (clinical). Clinical Information *A myelodysplastic syndrome characterized by the presence ... D46.2 Refractory anemia with excess of blasts [RAEB] D46.20 Refractory anemia with excess of blasts, unspecified ... D46.21 Refractory anemia with excess of blasts 1 D46.22 Refractory anemia with excess of blasts 2 ...
Cytokeratin expression by CD34 positive blasts in a case of refractory anaemia with excess of blasts in transformation (RAEB-t) ... Cytokeratin expression by CD34 positive blasts in a case of refractory anaemia with excess of blasts in transformation (RAEB-t) ... we report our experience with a case of refractory anaemia with excess of blasts in transformation (RAEB-t) in which the blasts ... Blasts were also found in peripheral blood (11%). Both bone marrow aspirate and biopsy demonstrated features suggestive of a ...
Refractory, with Excess of Blasts including blood tests, urine tests, swabs, diagnostic tests, lab tests, and pathology testing ... Anemia, Refractory, with Excess of Blasts: Introduction. *Symptoms of Anemia, Refractory, with Excess of Blasts *Home ... Diagnostic Tests for Anemia, Refractory, with Excess of Blasts. *Home Diagnostic Testing for Anemia, Refractory, with Excess of ... Prognosis of Anemia, Refractory, with Excess of Blasts. *Doctors and Medical Specialists for Anemia, Refractory, with Excess of ...
Refractory, with Excess of Blasts including cure research, prevention research, diagnostic research, and basic research. ... Clinical Trials for Anemia, Refractory, with Excess of Blasts. Some of the clinical trials for Anemia, Refractory, with Excess ... Diagnostic Tests for Anemia, Refractory, with Excess of Blasts. *Home Diagnostic Testing for Anemia, Refractory, with Excess of ... Prognosis of Anemia, Refractory, with Excess of Blasts. *Doctors and Medical Specialists for Anemia, Refractory, with Excess of ...
What is Anemia, refractory, with excess of blasts? Meaning of Anemia, refractory, with excess of blasts medical term. What does ... refractory, with excess of blasts in the Medical Dictionary? Anemia, refractory, with excess of blasts explanation free. ... Anemia, refractory, with excess of blasts , definition of Anemia, refractory, with excess of blasts by Medical dictionary https ... Refractory anemia with excess blasts (RAEB). Bone marrow with 5-20% blast cells, and higher risk of changing into acute ...
Learn in-depth information on Refractory Anemia with Excess Blasts, its causes, symptoms, diagnosis, complications, treatment, ... How can Refractory Anemia with Excess Blasts be Prevented?. Refractory Anemia with Excess Blasts may be avoided by:. *Limiting ... RAEB (Refractory Anemia with Excess Blasts). What is Refractory Anemia with Excess Blasts? (Definition/Background Information) ... Worsening of anemia. How is Refractory Anemia with Excess Blasts Treated?. Treatment measures for Refractory Anemia with Excess ...
Refractory anaemia with excess blasts (RAEB). A form of myelodysplasia characterised by the accumulation of immature white ... Refractory anaemia (RA) and refractory anaemia with sideroblasts (RAS) are the common forms of myelodysplasia. These are ... Refractory anaemia. A type of myelodysplasia which primarily affects red cell production by the bone marrow. In some cases the ... Blast cells. Blood blast cells that normally represent up to five per cent of the cells in the bone marrow and those cells ...
Refractory anemia with excess blasts (RAEB). RAEB means there is a low number of red blood cells in the blood and there may ... Refractory cytopenia with unilineage dysplasia (RCUD) and refractory anemia with ring sideroblasts (RAEB) are least likely to ... Refractory anemia with ring sideroblasts (RARS). RARS means there is a low number of red blood cells in the blood. The counts ... Refractory anemia (RA) means there is a low number of red blood cells in the blood. ...
Refractory anemia with excess blasts: McKenzies story. A winning athlete on the tennis court, McKenzie Haynes used that same ... spirit to meet the challenge of her young life-refractory anemia with excess blasts Type 1. Treatment at Childrens Mercy ... Aplastic anemia: Nicks story. One day Little League pitcher, Nick, just wasnt himself on the field. After a visit with his ...
Get help from medical experts to select the right refractory anemia with excess blasts doctor from top hospitals in Chennai. ... Get upto 25% discount on OPD fees of refractory anemia with excess blasts doctors at hospitals near you. ... View profile, fees, educational qualification, feedback and reviews of top refractory anemia with excess blasts specialists ... Best refractory anemia with excess blasts specialist in Chennai. ... Refractory Anemia With Excess Blasts Doctors in Chennai Matches ...
5.1.5. REFRACTORY ANEMIA WITH EXCESS BLASTS EARLY R&D MOLECULES. 5.1.6. REFRACTORY ANEMIA WITH EXCESS BLASTS INACTIVE AND ... 5.1.1. REFRACTORY ANEMIA WITH EXCESS BLASTS PHASE 3 MOLECULES. 5.1.2. REFRACTORY ANEMIA WITH EXCESS BLASTS PHASE 2 MOLECULES. ... 7. REFRACTORY ANEMIA WITH EXCESS BLASTS CLINICAL TRIALS SUMMARY. 7.1. REFRACTORY ANEMIA WITH EXCESS BLASTS PIPELINE ANALYSIS BY ... 5.1.3. REFRACTORY ANEMIA WITH EXCESS BLASTS PHASE 1 MOLECULES. 5.1.4. REFRACTORY ANEMIA WITH EXCESS BLASTS PRECLINICAL ...
refractory anemia. refractory anemia with ringed sideroblasts. refractory anemia with excess blasts. de novo myelodysplastic ... 53 with refractory anemia [RA], 33 with RA with ringed sideroblasts, and 44 with RA with excess blasts) will be accrued for ... refractory anemia [RA] vs RA with ringed sideroblasts vs RA with excess blasts). ... Genetic and Rare Diseases Information Center resources: Myelodysplastic Syndromes Sideroblastic Anemia Pyridoxine-refractory ...
For the treatment of several myelodysplastic syndrome subtypes including refractory and chronic myelomonocytic leukemias. New ... Refractory anemia with excess blasts. *Refractory anemia with excess blasts in transformation ... Refractory anemia. *Refractory anemia with ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia or requiring ... Suwanawiboon B, Sumida KN. 5-azacitidine: An alternative treatment of myelodysplastic syndromes in patient with refractory ...
Refractory Anemia With Excess Blasts Refractory Anemia With Excess Blasts in Transformation Drug: liposomal daunorubicin ... Anemia. Myelodysplastic Syndromes. Anemia, Refractory. Anemia, Refractory, with Excess of Blasts. Neoplasms by Histologic Type ... refractory anemia with excess blasts (RAEB), RAEB in transformation, or chronic myelomonocytic leukemia not in complete ... Myelodysplastic Syndrome With Excess Blasts Chronic Myeloproliferative Disorders Myelodysplastic/myeloproliferative Disease U.S ...
Refractory anemia with excess blasts-2 (RAEB-2 - defined as having 10-19% myeloblasts in the bone marrow and/or 5-19% blasts in ... Anemia, Refractory, with Excess of Blasts. Syndrome. Disease. Pathologic Processes. Neoplasms by Histologic Type. Neoplasms. ... Refractory anemia with excess blasts-1 (RAEB-1 - defined as having 5-9% myeloblasts in the bone marrow) ... Refractory anemia with excess blasts (RAEB - defined as having 5-20% myeloblasts in the bone marrow) ...
One patient had refractory anemia with excess blasts-2 (RAEB-2; CDX2 expression level, 66), and 1 patient had refractory ... refractory anemia with excess blasts; RNAi, RNA interference; RQ-PCR, real-time quantitative PCR; shRNA, short hairpin RNA; T- ... No CDX2 transcripts were detected in 1 patient with refractory anemia, 1 patient with RAEB-1, and 1 patient with RAEB-2. ... Excess cells from the fourth plating were continuously propagated in RPMI-1640 supplemented with 20% FBS and 10 μg/ml IL-3 (R&D ...
Myelodysplastic syndromes refractory anemia with excess of blasts-1. MDS RAEB-2. Myelodysplastic syndromes refractory anemia ... And monocyte/macrophage involved in inflammation-induced anemia result in an immediate decrease in hemoglobin synthesis. sNFI ...
Refractory anemia with ringed sideroblasts *Refractory anemia with excess blasts *Refractory anemia with excess blasts in ... Some types, considered low-risk, may cause mild to moderate anemia or other issues. Other types, considered high-risk, can ... Refractory cytopenia with multilineage dysplasia *Myelodysplastic syndrome associated with an isolated del(5q) chromosome ... Immune suppression for patients with features of aplastic anemia *Supportive drug therapy, which may include antibiotics to ...
Refractory anemia with excess blasts (RAEB). Bone marrow with 5-20% blast cells, and higher risk of changing into acute ... Refractory anemia with excess blasts in transformation (RAEBT). Bone marrow with 21-30% blast cells. This form is most likely ... Refractory anemia (RA). Bone marrow with less than 5% blast cells and abnormal red blood cell blasts ... Refractory anemia with ring sideroblasts (RARS). Bone marrow with less than 5% blasts and characteristic abnormalities in red ...
Also known as "refractory anemia excess blasts" (RAEB), this type of MDS shows signs of leukemic blast cells when the blood or ... Refractory Anemia With Excess Blasts in Transformation (RAEB-T). In the French-American-British (FAB) classification, an MDS ... Refractory Anemia with Ringed Sideroblasts (RARS). This is a form of anemia where the bone marrow produces ringed sideroblasts ... Clonal Anemia (Clonal Pancytopenia). Terms that may be used instead of "acquired" or "refractory" anemia. The terms "acquired" ...
anemia or refractory anemia with excess blasts ). The magnitude of the cost of care underscores a need for ... ... those diagnosed with refractory anemia with excess blasts or refractory cytopenia with multilineage dysplasia had a ... ... high-risk refractory anemia with excess blasts (RAEB) stages of MDS, the GMP population is increased in frequency ... ... subtypes refractory anaemia with excess blasts (RAEB) and RAEB in transformation. When analyzed per patient year ... ...
Luca on is pancytopenia resulting from chemotherapy is same as aplastic anemia: Aplastic anemia means something is wrong with ... trusted information on the use of Chemotherapy for Anemia: Dr. ... What is refractory anemia with excess of blasts? Dr. Michael ... A type of MDS: Refractory anemia with excess blasts is a type of myelodysplastic syndrome (MDS). The bone marrow will have ... Is anemia a symptom of Sickle Cell Anemia, or is Sickle Cell Anemia a type of anemia and if so do you have the same number of ...
  • Decitabine for injection is indicated for the treatment of patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts , refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups. (thefreedictionary.com)
  • 12) As a subgroup of the myelodysplastic syndromes, CMML shares the characteristics of trilineage dysplasia with refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts , and refractory anemia with excess blasts in transformation. (thefreedictionary.com)
  • Refractory anemia with ring sideroblasts (RARS). (thefreedictionary.com)
  • Patients are stratified according to myelodysplastic syndrome subclassification (refractory anemia [RA] vs RA with ringed sideroblasts vs RA with excess blasts). (clinicaltrials.gov)
  • PROJECTED ACCRUAL: A total of 130 patients (53 with refractory anemia [RA], 33 with RA with ringed sideroblasts, and 44 with RA with excess blasts) will be accrued for this study within 14-22 months. (clinicaltrials.gov)
  • In this study, SF3B1 mutations were identified in 10% of total cohort of 479 MDS patients and 61.8% of 34 patients with refractory anemia with ring sideroblasts (RARS). (nih.gov)
  • In refractory anemia (RA) and refractory anemia with ringed sideroblasts (RARS) a discrepancy is observed between the decreased in vitro erythroid colony formation and the normal or increased number of normoblasts in the bone marrow. (biomedsearch.com)
  • Refractory anemia with ringed sideroblasts (RARS)-Low numbers of red blood cells, and normal numbers of white blood cells and platelets. (skyridgemedcenter.com)
  • MDS includes many subtypes that are classified according to the number of blasts in the bone marrow, and the presence of ringed sideroblasts and specific chromosome abnormalities in the blood and bone marrow. (roswellpark.org)
  • RARS has the same characteristics as refractory anemia (above), except that the number of ringed sideroblasts exceeds 15 percent. (roswellpark.org)
  • The number of blasts is less than 5 percent and the number of ringed sideroblasts is less than 15 percent. (roswellpark.org)
  • The aspirate revealed a hypercellular marrow with a mild increase in blasts (5%-6%) and trilineage dyspoiesis, morphologic findings consistent with refractory anemia with excess blasts (RAEB-1). (thefreedictionary.com)
  • refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T), and chronic myelomonocytic leukemia (CMMoL). (thefreedictionary.com)
  • In this context, we report our experience with a case of refractory anaemia with excess of blasts in transformation (RAEB-t) in which the blasts were unexpectedly found to express cytokeratin (CK). (bmj.com)
  • Refractory anemia with excess blasts (RAEB). (thefreedictionary.com)
  • Refractory Anemia with Excess Blasts (RAEB) is a type of bone marrow disorder, called myelodysplastic syndrome (MDS). (dovemed.com)
  • I. Determine the maximum tolerated dose of SU5416 when administered with daunorubicin liposomal in patients with acute myeloid leukemia, refractory anemia with excess blasts (RAEB), RAEB in transformation, or chronic myelomonocytic leukemia not in complete remission 21-50 days after one course of induction chemotherapy. (clinicaltrials.gov)
  • subtypes refractory anaemia with excess blasts (RAEB) and RAEB in transformation. (aamds.org)
  • A female patient had been diagnosed with myelodysplastic syndrome, refractory anemia with excess blasts-2 (MDS, RAEB-2), at the age of 49. (hindawi.com)
  • Another classification schema directed toward MDS in childhood, mainly adapted by the European community, included MDS (refractory cytopenia, RAEB and RAEBT), JMML, and Down syndrome-specific diseases. (medscape.com)
  • Refractory anemia with excess blasts-1 (RAEB-1)-One or more blood cell types are too low. (skyridgemedcenter.com)
  • This is the same condition as RAEB-1, except that the number of blasts is greater than 10 percent but less than 20 percent. (roswellpark.org)
  • A myelodysplastic syndrome with blast excess (refractory anemia and blast excess II, RAEB II) could be confirmed. (dovepress.com)
  • On examination, she was found to have hepatosplenomegaly and petechiae, and full blood examination showed a profound pancytopenia with haemoglobin 82 g/L, neutrophil count 0.5 × 10 9 /L, monocyte count 0.9 × 10 9 /L, and platelet count 30 × 10 9 /L. A bone marrow biopsy was performed, and a diagnosis of refractory anaemia with excess blasts type 2 (RAEB-2) (16% blasts) was made. (hindawi.com)
  • Rather than another diagnosis of painful crisis, she had refractory anemia with excess blasts in transformation (RAEB-T). (bloodjournal.org)
  • If there are less than 20% blasts, the diagnosis is refractory anaemia with an excess of blasts (RAEB). (humpath.com)
  • Refractory cytopenia with multilineage dysplasia (RCMD)-This is the most common type of MDS. (skyridgemedcenter.com)
  • D46.A Refractory cytopenia with multilineage dyspla. (icd10data.com)
  • Refractory cytopenia with unilineage dysplasia (RCUD)-Low numbers of one type of blood cell, and normal numbers of the 2 others. (skyridgemedcenter.com)
  • 1) The administration of G-CSF, G-CSF + GM-CSF or G-CSF + EPO increased the number of platelets in some patients with aplastic anemia. (nii.ac.jp)
  • The blast can form a red blood cell, platelets, or one of several types of white blood cells. (roswellpark.org)
  • The blood film morphology can provide clues about hemolytic anemia , clumping of the platelets leading to spurious thrombocytopenia , or leukemia . (bionity.com)
  • Progress in the problem of relapsed or refractory acute myeloid leukemia. (bioportfolio.com)
  • The majority of patients with acute myeloid leukemia (AML) die from disease recurrence and historically, treatment options in both the relapsed and refractory settings of this disease have been limite. (bioportfolio.com)
  • Then, several combinations of hemopoietic factors were administered in children with aplastic anemia or acute leukemia. (nii.ac.jp)
  • Refractory anemia with excess blasts may progress to acute myeloid leukemia (AML). (oncolink.org)
  • The presence of any abnormalities in the blasts, or their signaling system, may disrupt their development and cause MDS. (dovemed.com)
  • who does not require transfusions, has no increase in blasts , nor any poor-risk cytogenetic abnormalities. (aamds.org)
  • Evolution of chromosome 7 abnormalities was seen most often in refractory patients who had failed to respond to therapy. (bloodjournal.org)
  • Laboratory evaluation showed refractory anemia with excess of blast, associated with cytogenetic abnormalities. (em-consulte.com)
  • 1 , 2 A differential white blood count was performed on 100 cells in the peripheral blood to determine the monocyte and peripheral blast count. (haematologica.org)
  • One patient with refractory anemia with excess blasts achieved a major platelet response of over 3-month duration. (aacrjournals.org)
  • A second patient with refractory anemia with excess blasts showed a minor platelet response of 25-day duration. (aacrjournals.org)
  • The World Health Organization (WHO) have recently recommended that the requisite blast percentage for a diagnosis of AML be 20% or greater, and this includes erythroid leukaemia. (humpath.com)
  • CK expression by myeloid blasts is a very uncommon finding-only three publications (two case reports and one in vitro study) dealing with this matter have been published so far. (bmj.com)
  • First, similar to CK detection reported in various lymphomatous or plasma cell disorders, 4 the immunohistochemical pattern of CK expression in myeloid blasts is also dot-like or perinuclear. (bmj.com)
  • In the myeloid cell line, the term 'blast cell' refers to myeloblasts or myeloid blasts. (verywellhealth.com)
  • A combination chemotherapy comprising idarubicin and Ara-C was ineffective, and 30% leukemic blasts remained in the BM. (hindawi.com)
  • The patient experienced a relapse of AML 17 months after the CBT and showed 20% leukemic blasts in the BM. (hindawi.com)
  • Granulocyte-macrophage colony-stimulating factor (GM-CSF) can stimulate proliferation of leukemic blasts and sensitize these cells to the cytotoxic effects of S-phase-specific drugs. (nature.com)
  • 10 By stimulating proliferation of leukemic blasts, GM-CSF can sensitize these cells to the cytotoxic effects of S-phase-specific drugs, such as cytarabine. (nature.com)
  • Cord blood is an FDA-approved treatment for nearly 80 diseases including numerous types of malignancies, anemias, inherited metabolic disorders and deficiencies of the immune system. (cryo-cell.com)
  • A phase I/II study was done to determine safety and efficacy of everolimus in patients with relapsed or refractory hematologic malignancies. (aacrjournals.org)
  • 2) The effect of EPO to increase platelet counts was confirmed in the EPO therapy for anemia of prematurity. (nii.ac.jp)
  • The WHO classification moved CMML to myeloproliferative/myelodysplastic disorders, and defined CMML I and CMML II according to medullary and peripheral blast count. (haematologica.org)
  • 5 The WHO now added cytogenetic and/or molecular examinations to exclude bcr-abl positive CML 6 and proposed to separate two CMML subsets according peripheral and medullary blast counts. (haematologica.org)
  • 10% medullary and ≤ 5% peripheral blasts, and CMML II with 10-19% medullary and/or 5-19% peripheral blasts. (haematologica.org)
  • Medullary blasts were higher in CMML II and the proportion of monocytes was greater in CMML I. Medullary blasts correlated only weakly with WBC, monocytes and LDH. (haematologica.org)
  • Antibodies that attach to and destroy lymphocytes.This may be used clinically by injection into a vein, for example, in aplastic anaemia or in other conditions where the body's immune system is being harmful. (leukaemia.org.au)
  • GlobalData's clinical trial report, "Refractory Anemia with Excess Blasts Global Clinical Trials Review, H1, 2018 provides an overview of Refractory Anemia With Excess Blasts clinical trials scenario. (marketresearch.com)
  • This report provides top line data relating to the clinical trials on Refractory Anemia With Excess Blasts. (marketresearch.com)
  • A retrospective study comparing azacitidine with decitabine in Chinese patients with refractory anemia with excess blast based on two clinical trials in a single center. (nih.gov)
  • This subtype causes refractory (treatmentresistant) anemia associated with a deletion of the long arm (q) of chromosome 5, designated "del(5q). (lls.org)
  • Which is the connection between hypoxia or sickle cell anemia and pica for foam? (healthtap.com)
  • Researchers are looking into the benefits of stem cell transplants to treat many forms of cancer, sickle cell disease and certain rare types of anemia. (nortonhealthcare.com)
  • Although there is no available clinical data as references in performing the third allogeneic HSCT currently, this has been performed sporadically at experienced transplant centers as one of options for treatment of patients with multiple relapsed AML, because the HSCT is regarded as the best way to achieve potential cure for refractory or relapsed AML. (hindawi.com)